Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants

Andrew E. Kyles, Clare R. Gregory, Arthur L. Craigmill, Stephen M Griffey, Joshua Jackson, Scott D Stanley

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective - To describe pharmacokinetics of multidose oral administration of tacrolimus in healthy cats and evaluate the efficacy of tacrolimus in the prevention of allograft rejection in cats with renal transplants. Animals - 6 healthy research cats. Procedure - Cats received tacrolimus (0.375 mg/kg, PO, q 12 h) for 14 days. Blood tacrolimus concentrations were measured by a high performance liquid chromatography-mass spectrometry assay. Each cat received an immunogenically mismatched renal allograft and native kidney nephrectomy. Tacrolimus dosage was modified to maintain a target blood concentration of 5 to 10 ng/mL. Cats were euthanatized if plasma creatinine concentration exceeded 7 mg/dL, body weight loss exceeded 20%, or on day 50 after surgery. Kaplan-Meier survival curves were plotted for 6 cats treated with tacrolimus and for 8 cats with renal transplants that did not receive immunosuppressive treatment. Results - Mean, (± SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 ± 9.8 hours, 0.77 ± 0.37 hours, 275 ± 31.8 ng/mL, and 161 ± 168 hours × ng/mL, respectively. Tacrolimus treated cats survived longer (median, 44 days; range, 24 to 52 days) than untreated cats (median, 23 days- range, 8 to 34 days). On histologic evaluation, 3 cats kad evidence of acute-active rejection, 1 cat had necrotizing vasculitis, and 2 cats euthanatized at study termination had normal appearing allografts. Conclusions and Clinical Relevance - Tacrolimus may be an effective immunosuppressive agent for renal transplantation in cats.

Original languageEnglish (US)
Pages (from-to)926-934
Number of pages9
JournalAmerican Journal of Veterinary Research
Volume64
Issue number7
DOIs
StatePublished - Jul 1 2003

Fingerprint

tacrolimus
graft rejection
kidney transplant
Tacrolimus
oral administration
pharmacokinetics
Allografts
Oral Administration
Cats
Pharmacokinetics
cats
Transplants
Kidney
immunosuppressive agents
allografting
Immunosuppressive Agents
blood
kidneys
vasculitis
Kaplan-Meier Estimate

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. / Kyles, Andrew E.; Gregory, Clare R.; Craigmill, Arthur L.; Griffey, Stephen M; Jackson, Joshua; Stanley, Scott D.

In: American Journal of Veterinary Research, Vol. 64, No. 7, 01.07.2003, p. 926-934.

Research output: Contribution to journalArticle

@article{1d3e3876c3d4499da972156c7a1ab1f3,
title = "Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants",
abstract = "Objective - To describe pharmacokinetics of multidose oral administration of tacrolimus in healthy cats and evaluate the efficacy of tacrolimus in the prevention of allograft rejection in cats with renal transplants. Animals - 6 healthy research cats. Procedure - Cats received tacrolimus (0.375 mg/kg, PO, q 12 h) for 14 days. Blood tacrolimus concentrations were measured by a high performance liquid chromatography-mass spectrometry assay. Each cat received an immunogenically mismatched renal allograft and native kidney nephrectomy. Tacrolimus dosage was modified to maintain a target blood concentration of 5 to 10 ng/mL. Cats were euthanatized if plasma creatinine concentration exceeded 7 mg/dL, body weight loss exceeded 20{\%}, or on day 50 after surgery. Kaplan-Meier survival curves were plotted for 6 cats treated with tacrolimus and for 8 cats with renal transplants that did not receive immunosuppressive treatment. Results - Mean, (± SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 ± 9.8 hours, 0.77 ± 0.37 hours, 275 ± 31.8 ng/mL, and 161 ± 168 hours × ng/mL, respectively. Tacrolimus treated cats survived longer (median, 44 days; range, 24 to 52 days) than untreated cats (median, 23 days- range, 8 to 34 days). On histologic evaluation, 3 cats kad evidence of acute-active rejection, 1 cat had necrotizing vasculitis, and 2 cats euthanatized at study termination had normal appearing allografts. Conclusions and Clinical Relevance - Tacrolimus may be an effective immunosuppressive agent for renal transplantation in cats.",
author = "Kyles, {Andrew E.} and Gregory, {Clare R.} and Craigmill, {Arthur L.} and Griffey, {Stephen M} and Joshua Jackson and Stanley, {Scott D}",
year = "2003",
month = "7",
day = "1",
doi = "10.2460/ajvr.2003.64.926",
language = "English (US)",
volume = "64",
pages = "926--934",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants

AU - Kyles, Andrew E.

AU - Gregory, Clare R.

AU - Craigmill, Arthur L.

AU - Griffey, Stephen M

AU - Jackson, Joshua

AU - Stanley, Scott D

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Objective - To describe pharmacokinetics of multidose oral administration of tacrolimus in healthy cats and evaluate the efficacy of tacrolimus in the prevention of allograft rejection in cats with renal transplants. Animals - 6 healthy research cats. Procedure - Cats received tacrolimus (0.375 mg/kg, PO, q 12 h) for 14 days. Blood tacrolimus concentrations were measured by a high performance liquid chromatography-mass spectrometry assay. Each cat received an immunogenically mismatched renal allograft and native kidney nephrectomy. Tacrolimus dosage was modified to maintain a target blood concentration of 5 to 10 ng/mL. Cats were euthanatized if plasma creatinine concentration exceeded 7 mg/dL, body weight loss exceeded 20%, or on day 50 after surgery. Kaplan-Meier survival curves were plotted for 6 cats treated with tacrolimus and for 8 cats with renal transplants that did not receive immunosuppressive treatment. Results - Mean, (± SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 ± 9.8 hours, 0.77 ± 0.37 hours, 275 ± 31.8 ng/mL, and 161 ± 168 hours × ng/mL, respectively. Tacrolimus treated cats survived longer (median, 44 days; range, 24 to 52 days) than untreated cats (median, 23 days- range, 8 to 34 days). On histologic evaluation, 3 cats kad evidence of acute-active rejection, 1 cat had necrotizing vasculitis, and 2 cats euthanatized at study termination had normal appearing allografts. Conclusions and Clinical Relevance - Tacrolimus may be an effective immunosuppressive agent for renal transplantation in cats.

AB - Objective - To describe pharmacokinetics of multidose oral administration of tacrolimus in healthy cats and evaluate the efficacy of tacrolimus in the prevention of allograft rejection in cats with renal transplants. Animals - 6 healthy research cats. Procedure - Cats received tacrolimus (0.375 mg/kg, PO, q 12 h) for 14 days. Blood tacrolimus concentrations were measured by a high performance liquid chromatography-mass spectrometry assay. Each cat received an immunogenically mismatched renal allograft and native kidney nephrectomy. Tacrolimus dosage was modified to maintain a target blood concentration of 5 to 10 ng/mL. Cats were euthanatized if plasma creatinine concentration exceeded 7 mg/dL, body weight loss exceeded 20%, or on day 50 after surgery. Kaplan-Meier survival curves were plotted for 6 cats treated with tacrolimus and for 8 cats with renal transplants that did not receive immunosuppressive treatment. Results - Mean, (± SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 ± 9.8 hours, 0.77 ± 0.37 hours, 275 ± 31.8 ng/mL, and 161 ± 168 hours × ng/mL, respectively. Tacrolimus treated cats survived longer (median, 44 days; range, 24 to 52 days) than untreated cats (median, 23 days- range, 8 to 34 days). On histologic evaluation, 3 cats kad evidence of acute-active rejection, 1 cat had necrotizing vasculitis, and 2 cats euthanatized at study termination had normal appearing allografts. Conclusions and Clinical Relevance - Tacrolimus may be an effective immunosuppressive agent for renal transplantation in cats.

UR - http://www.scopus.com/inward/record.url?scp=0038015259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038015259&partnerID=8YFLogxK

U2 - 10.2460/ajvr.2003.64.926

DO - 10.2460/ajvr.2003.64.926

M3 - Article

VL - 64

SP - 926

EP - 934

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 7

ER -